Novo Nordisk's Buyback Machine Grinds On While the Bear Case Hardens

Novo Nordisk's buyback pace remains steady despite a 27% stock drop, pipeline setbacks, and a Deutsche Bank downgrade ahead of its Capital Markets Day.

The arithmetic of Novo Nordisk's share repurchase program tells a story of its own. Between February 4 and August 28, the Danish drugmaker acquired 30,979,179 B-shares at an average price of 281.08 Danish kroner, forking out 8.71 billion kroner in total. That leaves the 15 billion kroner, twelve-month program roughly half-spent — hardly the behavior of a management team rattled by the market's recent mood swings.

The pace barely flinched in late August either. In the week spanning August 17–21 alone, Novo bought another 1,045,000 B-shares, lifting cumulative purchases under the program to 15,170,000 shares worth around 4.59 billion kroner. By August 21, the company held 43,969,876 B-shares in treasury, equivalent to 1.0 percent of its share capital.

A Stock Trading in a Wide, Uncomfortable Band

The buyback discipline stands in sharp contrast to the price action. Novo Nordisk shares closed Friday at 40.09 euros, down 1.8 percent on the day. The stock has shed 8.9 percent since the start of the year and sits 17 percent below its level twelve months ago. From the 52-week high of 54.86 euros, touched in late January, the shares have fallen 27 percent. They remain roughly 33 percent above the 52-week low of 30.25 euros, a trough carved out as recently as early March.

That range underscores just how turbulent trading has become. Annualized 30-day volatility stands at 41 percent — an unusually elevated reading for a large-cap pharmaceutical name. The fact that Novo has been buying back stock at an average price well above current levels invites questions about timing, though the steady, schedule-driven approach suggests strategic capital allocation rather than opportunistic market timing.

Pipeline Setbacks and a Rival's Momentum

The sell-off has not been random. Eli Lilly's oral obesity drug, Foundayo, launched in the UK in August and is now awaiting approval in more than 40 markets, intensifying competition in the lucrative weight-loss arena. Closer to home, the failed cardiovascular study for Ziltivekimab has clouded pipeline prospects.

Deutsche Bank responded in late August by downgrading the stock to "Sell" with a price target of 265 Danish kroner, citing expectations of slower growth in 2027, the Ziltivekimab disappointment, and meaningful patent-expiry risks in the second half of the decade. The bank reaffirmed its bearish stance in early September even as the shares briefly firmed. J.P. Morgan has adopted a more cautious posture with a Hold rating.

Yet the pipeline is not standing still. The company has reported progress on an injectable obesity medication in a pivotal Phase 3 study and has advanced a new obesity candidate, NNC0721-8060, into first-in-human trials. Whether that offsets the bearish thesis is a question investors hope the upcoming capital markets day will answer.

A London Showdown for the Bulls and Bears

All eyes now turn to September 21, when Novo Nordisk hosts its Capital Markets Day in London. Management is expected to lay out fresh strategic targets alongside a comprehensive review of strategy, R&D pipeline, operations, and business development. For a stock nursing double-digit losses and facing pointed analyst criticism, the event carries outsized weight — a chance for the company to reset the narrative or confirm the skeptics' worst fears.